Страна: Індонезія
мова: індонезійська
Джерело: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
PANTOPRAZOLE SODIUM SESQUIHYDRATE
TAKEDA INDONESIA - Indonesia
PANTOPRAZOLE SODIUM SESQUIHYDRATE
40 MG/VIAL
SERBUK INJEKSI
DUS, 1 VIAL @ 40 MG
TAKEDA Gmbh - Germany
2016-01-20
Insert leaflet Pantozol ® i.v. ACTIVE INGREDIENT: PANTOPRAZOLE SODIUM SESQUIHYDRATE COMPOSITION Each vial contains 45.1 mg Pantoprazole sodium sesquihydrate (equivalent to pantoprazole 40 mg). PHARMACOLOGICAL PROPERTIES ATC Code : A02BC02 MECHANISM OF ACTION Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific action on the proton pumps of the parietal cells. Pantoprazole is converted to its active form in the acidic environment in the parietal cells where its inhibits the H+, K+-ATPase enzyme, i.e. the final stage in the production of hydrochloric acid in the stomach. The inhibition is dose-dependent and affects both basal and stimulated acid secretion. As with other proton pump inhibitors and H2 receptor inhibitors, treatment with pantoprazole causes a reduced acidity in the stomach and thereby an increase in gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since pantoprazole binds to the enzyme distal to the cell receptor level, the substance can affect hydrochloric acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin). The effect is the same whether the product is given orally or intravenously. INDICATIONS - Duodenal ulcer - Gastric ulcer - Moderate and severe cases of inflammation of the oesophagus (reflux esophagitis) - For the treatment of pathological hypersecretory condition associated with Zollinger-Ellison-Syndrome and other neoplastic conditions POSOLOGY AND METHOD OF ADMINISTRATIONS The intravenous administration of Pantozol® i.v. is recommended only if oral application is not appropriate. • RECOMMENDED DOSAGE Duodenal ulcer, gastric ulcer, moderate and severe reflux esophagitis The recommended intravenous dosage is one vial (40 mg pantoprazole) Pantozol® i.v. per day. Long-term management of Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions Patients should start their treatment with a daily dose of 80 mg Pantozol® i Прочитайте повний документ